Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis.
暂无分享,去创建一个
S. Vatner | D. Vatner | Lin Yan | M. Schwarz | Chujun Yuan | P. Solanki
[1] B. Gersh,et al. Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. , 2014, Journal of molecular and cellular cardiology.
[2] Charles E. Murry,et al. Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate Non-Human Primate Hearts , 2014, Nature.
[3] M. Rota,et al. Human heart failure: is cell therapy a valid option? , 2014, Biochemical pharmacology.
[4] J. Marín-García,et al. Myocardial regeneration of the failing heart , 2013, Heart Failure Reviews.
[5] W. R. MacLellan,et al. Regeneration potential of adult cardiac myocytes , 2013, Cell Research.
[6] J. Loscalzo,et al. Cardiomyogenesis in the Aging and Failing Human Heart , 2012, Circulation.
[7] C. Murry,et al. Heart regeneration , 2011, Nature.
[8] P. Goichberg,et al. Cardiomyogenesis in the Adult Human Heart , 2010, Circulation research.
[9] N. Awasthi,et al. EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer , 2010, Annals of Surgical Oncology.
[10] N. Awasthi,et al. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation , 2010, Cancer biology & therapy.
[11] R. Bellazzi,et al. TWEAK is a positive regulator of cardiomyocyte proliferation. , 2010, Cardiovascular research.
[12] I. Kron,et al. Stem cell therapy for ischemic heart disease: where are we? , 2009, Current opinion in organ transplantation.
[13] K. Nakayama,et al. Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase. , 2008, Cardiovascular research.
[14] Christine L. Mummery,et al. Embryonic Stem (es) Cells from Mice and Primates Can Differentiate into Any Cell Type in the Adult Body Stem Cells in Fetal and Adult Hearts Stem-cell-based Therapy and Lessons from the Heart Insight Review , 2022 .
[15] A. Kornelyuk,et al. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. , 2007, Experimental oncology.
[16] Lila R Collins,et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.
[17] W. R. MacLellan,et al. Cardiac myocyte cell cycle control in development, disease, and regeneration. , 2007, Physiological reviews.
[18] S. Epstein,et al. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. , 2007, Annual review of pathology.
[19] M. Schwarz,et al. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. , 2004, The Journal of surgical research.
[20] M. Schwarz,et al. Epithelial-mesenchymal interactions are linked to neovascularization. , 2004, American journal of respiratory cell and molecular biology.
[21] D. Warburton,et al. Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis , 2000, Mechanisms of Development.
[22] S. Libutti,et al. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). , 2000, Cytokine.
[23] E. Kohn,et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. , 2000, Microvascular research.
[24] M. Schwarz,et al. Temporo‐spatial distribution of endothelial‐monocyte activating polypeptide II, an anti‐angiogenic protein, in the mouse embryo , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[25] Jun Li,et al. Endothelial-Monocyte Activating Polypeptide Ii, a Novel Antitumor Cytokine That Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells , 1999, The Journal of experimental medicine.
[26] E. Topol,et al. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. , 1999, International journal of cardiology.
[27] J. Isner,et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.
[28] PieroAnversa,et al. Ventricular Myocytes Are Not Terminally Differentiated in the Adult Mammalian Heart , 1998 .
[29] R. Katori,et al. Basic Fibroblast Growth Factor Increased Regional Myocardial Blood Flow and Limited Infarct Size of Acutely Infarcted Myocardium in Dogs , 1998, Angiology.
[30] M. Zimmerman,et al. A thyroid hormone analog stimulates angiogenesis in the post-infarcted rat heart. , 1998, Journal of molecular and cellular cardiology.
[31] M. Franklin,et al. Cardiomyocyte DNA synthesis and binucleation during murine development. , 1996, The American journal of physiology.
[32] L. Brown,et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.
[33] S. Libutti,et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. , 1994, The Journal of biological chemistry.
[34] Z. Darżynkiewicz,et al. Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing-induced cardiomyopathy in rats. , 1994, Circulation research.
[35] D. Stern,et al. Endothelial-monocyte activating polypeptides (EMAPs): tumor derived mediators which activate the host inflammatory response. , 1993, Behring Institute Mitteilungen.
[36] P. Familletti,et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. , 1992, The Journal of biological chemistry.
[37] R. Zak. Development and Proliferative Capacity of Cardiac Muscle Cells , 1974, Circulation research.
[38] S. Vatner,et al. Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload , 2012, Basic Research in Cardiology.
[39] N. Awasthi,et al. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling , 2009, Laboratory Investigation.
[40] N. Mochizuki,et al. Expression of vascular endothelial growth factor in human myocardial infarction , 2005, Heart and Vessels.
[41] B. Franc,et al. Potential role for antiangiogenic proteins in the myocardial infarction repair process. , 2004, The Journal of surgical research.
[42] D. Warburton,et al. EMAP II: a modulator of neovascularization in the developing lung. , 1999, The American journal of physiology.